AbCellera Biologics (ABCL) Asset Utilization Ratio (2021 - 2026)

AbCellera Biologics' Asset Utilization Ratio history runs 6 years deep, the most recent figure standing at 0.06 for Q1 2026.

• Quarterly Asset Utilization Ratio rose 247.9% year-over-year to 0.06 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.06 (up 247.9% YoY) and the FY2025 annual result came in at 0.06, up 173.14% from the prior year.
• Asset Utilization Ratio was 0.06 for Q1 2026 at AbCellera Biologics, up from 0.06 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.38 in Q3 2022 and bottomed at 0.02 in Q1 2025.
• A 5-year average of 0.11 and a median of 0.03 in 2023 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio plunged 91.92% — and 2026, when it surged 247.9%.
• AbCellera Biologics' Asset Utilization Ratio stood at 0.31 in 2022, then plunged by 91.92% to 0.03 in 2023, then dropped by 17.37% to 0.02 in 2024, then jumped by 164.43% to 0.06 in 2025, then grew by 7.37% to 0.06 in 2026.
• Business Quant data shows ABCL's Asset Utilization Ratio at 0.06 in Q1 2026, 0.06 in Q4 2025, and 0.03 in Q3 2025.